Diabetes tech developers have high hopes for the year ahead, some of which have already come to fruition. Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes. […]
Tandem Diabetes Care
Tandem Diabetes warns on some t:slim X2 insulin pumps
Tandem Diabetes Care (Nasdaq:TNDM) issued an urgent field safety notice in Europe for its t:slim X2 insulin pump with Basal-IQ technology. The notice, dated February 2022, alerts users of Tandem’s insulin pump with a software version of 6.3.0.1 that there may be a potential safety risk when using the pump within its normal specifications. Tandem’s […]
Tandem Diabetes Care beats Street on Q4 sales, posts EPS miss
Tandem Diabetes Care (NASDAQ:TNDM) shares were slightly up on fourth-quarter results that beat the consensus revenue forecast. The San Diego-based company posted profits of $10.8 million, or 16¢ per share, on sales of $210 million for the three months ended Dec. 31, 2021, for a 36.4% bottom-line slide on sales growth of 24.9%. Tandem Diabetes […]
Tandem Diabetes Care wins FDA clearance for insulin dosing via smartphone app
Tandem Diabetes Care (NASDAQ:TNDM) today announced FDA clearance of bolus insulin dosing on the t:slim X2 insulin pump using the t:connect mobile app. Company officials said the t:connect mobile app is now the first FDA-cleared smartphone app for insulin delivery on both the iOS and Android operating systems. Tandem Diabetes Care plans to roll out […]
Report: Insulet expects delays in FDA review for Omnipod 5 with launch pushed back
The highly anticipated launch of the Insulet (NSDQ:PODD) Omnipod 5 may not come as soon as thought as an FDA review drags on. SeekingAlpha reported that Insulet CEO Shacey Petrovic, speaking at the Nasdaq Investor Conference, said the regulatory agency will likely not complete its review of the next-generation Omnipod 5 before the end of […]
Tandem Diabetes Care expands leadership team
Automated insulin delivery technology developer Tandem Diabetes Care (NSDQ:TNDM) announced new appointments in three executive leadership positions. San Diego-based Tandem named Rick Carpenter as CTO, Libba Sapitsky as SVP of Customer Care and Rizwan Pervez as SVP of Quality and Regulatory. According to a news release, Carpenter, a veteran of more than 30 years in […]
Tandem nosedives after hours despite strong Q3, raised guidance
Tandem Diabetes Care (NSDQ:TNDM) shares took a massive hit after hours today on third-quarter results that beat the consensus forecast. TNDM shares were down 12.3% at $124.01 per share after the markets closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down 0.1%. The […]
Tandem Diabetes Care rises after hours on Street-beating Q2
Tandem Diabetes Care (NSDQ:TNDM) shares ticked up after hours today on second-quarter results that came in well ahead of the consensus forecast. The San Diego-based company posted profits of $4 million on sales of $172.1 million for the three months ended June 30, 2021, for a massive bottom-line gain from losses of -$27.1 million this […]
Tandem Diabetes Care touts study results for insulin pump with closed-loop technology
Tandem Diabetes Care (NSDQ:TNDM) today shared real-world data on its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology. Presenting at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), the company touted immediate and sustained improvements in time-in-range (TIR) observed in more than 9,000 people with diabetes using the system […]
Tandem Diabetes Care beats The Street in Q1, raises guidance
Tandem Diabetes Care (NSDQ:TNDM) narrowed its losses year-over-year in Q1, with results beating the consensus forecast on Wall Street. The San Diego-based company yesterday evening posted losses of –$5 million, or –8¢ per share, on sales of $141 million for the three months ended March 31, 2021, reducing losses by nearly two-thirds on sales growth […]
